The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2024Qualitative Evaluation of Draft Questionnaires for Patient-reported Outcome Measures of Non-motor Symptoms in Early-stage Parkinson's Disease
Study Rationale: This project seeks to address an unmet need for fit-for-purpose, clinical outcome assessments for early-stage Parkinson’s disease (PD) to be used in clinical trials to capture the...
-
MJFF Research Grant, 2010Technology for Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
We seek to create and enhance a secure database, accessible by collaborators with customizable, user-friendly, web-based entry for clinical, genetic and pedigree information. This... -
Rapid Response Innovation Awards, 2009The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets... -
Therapeutics Development Initiative, 2011Testing of Ambroxol in the Thy1-Alpha-Synuclein Pre-clinical Model of Parkinson's disease
Objective/Rationale:
Biochemical evidence suggests that blocking the maturation of a natural enzyme, glucocerebrosidase (GCase), can cause the build-up of alpha-synuclein deposits in neurons. Such... -
Dyskinesia Challenge, 2012The Effects of Memantine on Levodopa Induced Dyskinesias (LIDs) in MPTP-treated Pre-clinical Models
Objective/Rationale:
Levodopa is the mainstay of treatment for the motor symptoms of Parkinson’s disease. Unfortunately one of the long term side effects of levodopa treatment is the development of... -
Therapeutics Development Initiative, 2012Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease
Objective/Rationale:
Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.